Gene: MYBL1
Official Full Name: MYB proto-oncogene like 1provided by HGNC
Gene Summary: Enables DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in positive regulation of transcription by RNA polymerase II. Located in nucleoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO04426 | MYBL1 Knockout cell line (HeLa) | Human | MYBL1 | 1:3~1:6 | Negative | Online Inquiry |
KO04427 | MYBL1 Knockout cell line (HCT 116) | Human | MYBL1 | 1:2~1:4 | Negative | Online Inquiry |
KO04428 | MYBL1 Knockout cell line (HEK293) | Human | MYBL1 | 1:3~1:6 | Negative | Online Inquiry |
KO04429 | MYBL1 Knockout cell line (A549) | Human | MYBL1 | 1:3~1:4 | Negative | Online Inquiry |
MYBL1 Gene Knockout Cell Lines represent a cutting-edge biological research tool designed to facilitate investigations into MYBL1 gene function and its implications in various biological processes, particularly in the context of cancer and cellular proliferation. By utilizing CRISPR/Cas9 technology, these knockout cell lines allow researchers to create cells that are genetically modified to lack the MYBL1 gene, providing a powerful mechanism to study the downstream effects of MYBL1 loss-of-function.
Key functions of these cell lines include their ability to elucidate the role of MYBL1 in cell cycle regulation, differentiation, and apoptosis, as well as its modulation of other oncogenes and tumor suppressors. The loss of MYBL1 has been correlated with various malignancies, making these cell lines invaluable for exploring novel therapeutic strategies that target MYBL1-related pathways.
The scientific significance of MYBL1 Gene Knockout Cell Lines extends beyond basic research; they hold great potential in translational medicine by providing a platform for assessing the efficacy of targeted therapies. In clinical settings, understanding the role of MYBL1 could lead to improved prognostic markers and treatment strategies, tailoring patient care in oncology.
These knockout cell lines present distinct advantages over traditional gene deletion methods, such as stable knockdown technologies. The precision and efficiency of CRISPR/Cas9 ensure a complete and uniform knockout of the MYBL1 gene, enabling reliable and reproducible results. Additionally, with less time required for validation and fewer off-target effects, researchers can expedite their experiments and obtain meaningful insights quicker than with competing products.
For researchers and clinicians invested in cancer biology and gene function studies, MYBL1 Gene Knockout Cell Lines provide an essential tool for advancing knowledge and therapeutic responses in clinical settings. With extensive expertise in developing cutting-edge biological products, our company is committed to equipping the scientific community with innovative solutions that aid in groundbreaking research.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.